Neuropathic pain is accompanied by neuroimmune activation in dorsal horn of spinal cord. We have observed that in animal models this activation is characterized by an increased expression of transmembrane tumor necrosis factor a (mTNFa) without the release of soluble tumor necrosis factor a (sTNFa).
a b s t r a c t
Neuropathic pain is accompanied by neuroimmune activation in dorsal horn of spinal cord. We have observed that in animal models this activation is characterized by an increased expression of transmembrane tumor necrosis factor a (mTNFa) without the release of soluble tumor necrosis factor a (sTNFa).
Herein we report that the pain-related neurotransmitter peptide substance P (SP) increases the expression of mTNFa without the release of sTNFa from primary microglial cells. We modeled this interaction using an immortalized microglial cell line; exposure of these cells to SP also resulted in the increased expression of mTNFa but without any increase in the expression of the TNF-cleaving enzyme (TACE) and no release of sTNFa. In order to evaluate the biological function of uncleaved mTNFa, we transfected COS-7 cells with a mutant full-length TNFa construct resistant to cleavage by TACE. Coculture of COS-7 cells expressing the mutant TNFa with microglial cells led to microglial cell activation indicated by increased OX42 immunoreactivity and release of macrophage chemoattractant peptide 1 (CCL2) by direct cell-cell contact. These results suggest a novel pathway through which the release of SP by primary afferents activates microglial expression of mTNFa, establishing a feed-forward loop that may contribute to the establishment of chronic pain.
Published by Elsevier B.V. on behalf of International Association for the Study of Pain.
Introduction
Acute painful stimuli are transmitted from the periphery by firing of nociceptive neurons in the DRG. Trauma to or inflammation of peripheral nerves results in sustained increased electrical activity in the undamaged C fibers [12] that leads to transcriptional and post-translational changes in second order neurons in the dorsal horn of spinal cord that are characteristic of chronic pain [41, 50] . Substantial evidence indicates that peripheral nerve damage or inflammation results in the activation of microglia and astrocytes in the dorsal horn that plays an important role in the pathogenesis of neuropathic pain [19, 36] . In the setting of peripheral nerve damage activated glia express proinflammatory cytokines including TNFa, interleukin (IL)-1b, and IL-6 [2,47,49]. Administration of drugs that block the effects of these cytokines [3, 40, 45] or that block glial activation [24, 34, 46] can be used to prevent or reverse neuropathic pain. Pain-related effects similar to those seen in neuropathic pain can be reproduced by activation of spinal cord glia [28] or by direct intrathecal administration of proinflammatory cytokines [7] in the absence of nerve injury.
Several lines of evidence indicate that tumor necrosis factor a (TNFa) plays a key role in the development of chronic pain. In response to peripheral nerve crush, in toxic neuropathy or after spinal cord injury the amount of TNFa in spinal microglia and astrocytes is increased [11, 23, 30] . In the chronic constriction injury model of peripheral neuropathic pain, neutralizing antibodies directed against TNFa or the p55 TNF receptor (TNFR) reduce thermal hyperalgesia and mechanical allodynia [42] and intrathecal administration of the recombinant p75 soluble TNFR (sTNFR) peptide (etanercept) prior to selective spinal nerve ligation reduces mechanical allodynia [40, 44] . In contrast to the classic inflammatory response that is characterized by the release of sTNFa, in states of neuropathic pain created by spinal hemisection or selective spinal nerve ligation, the increase in spinal TNFa mRNA correlates with an increase in the full-length membrane-spanning TNFa (mTNFa) protein [18, 33] without a parallel release of soluble TNFa (sTNFa). By immunohistochemistry, we found that mTNFa was localized to restricted patches in the membranes of microglia in the spinal dorsal horn [18, 33] .
TNFa is a member of the superfamily of type II transmembrane proteins containing an intracellular N-terminus. The full-length mTNFa (26 kDa) is cleaved by the inducible TNF alpha converting enzyme (TACE) to release the diffusible peptide (sTNFa, 17 kDa) that is biologically active as self-assembling non-covalent bound 
